Navigation Links
Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
Date:5/27/2008

BURLINGAME, Calif., May 27 /PRNewswire/ -- Epitomics, Inc., the rabbit monoclonal antibody company, announced today that it has developed its 1000th new rabbit monoclonal antibody. Each antibody has been created, tested and QC'd in house utilizing Epitomics' proprietary rabbit monoclonal antibody technology. "We are very excited to have reached this milestone in a short period of time. This demonstrated the robustness of our technology and development pipeline," said Dr. Guo-Liang Yu, President and CEO of Epitomics Inc. "While thousands of antibodies exist in the market our Rabbit Monoclonal antibody technology has allowed for the development of monoclonal antibodies that were previously only possible to develop as a polyclonal antibody if at all," said Dr. Yu, "many of the targets for which we have developed a Rabbit Monoclonal, no other monoclonal antibody had existed previously."

Epitomics is the exclusive provider of a proprietary method for making monoclonal antibodies from rabbits rather the conventional method of starting with mice. The advantages of Epitomics' rabbit monoclonal antibodies (RabMAbs(TM)) include high specificity and affinity which provide excellent results in a variety of commonly used immunoassays. "Each one of our rabbit monoclonal antibodies undergoes stringent testing in five major immunoassays including Western blotting, Immunohistochemistry, Immunofluorescence, Immunopreciptation and Flow Cytometry, before being released," said Dr. Peter Li, Senior VP of Product Development, "our rabbit monoclonals are among the most extensively characterized antibodies available." The complete list of Rabbit Monoclonals including background information and data for each antibody is available for viewing on Epitomics website.

About Epitomics

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The Company utilizes a unique and proprietary RabMAb(TM) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. The Company is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. More information about Epitomics can be found at http://www.epitomics.com


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NicOx Announces Departure of Damian Marron for CEO Position
2. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
3. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
4. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
5. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
6. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
7. Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System
8. Amarin Announces Completion of the First Tranche of $60 Million Private Placement
9. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
10. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
11. Biopure Announces 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):